EMEA-003566-PIP01-23 - paediatric investigation plan
camrelizumab
PIPHuman
Key facts
- Active Substance
- camrelizumab
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0154/2024
- PIP number
- EMEA-003566-PIP01-23
- Pharmaceutical form(s)
- Powder for solution for injection
- Condition(s) / indication(s)
- Treatment of hepatocellular carcinoma
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Luzsana Biotechnology Europe
E-mail: regulatoryeu@luzsana.com
Tel.: +41 792406071- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date